{
    "nctId": "NCT04666805",
    "briefTitle": "Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast",
    "officialTitle": "Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With Hormone Receptor-positive Intraductal Carcinoma of the Breast: A Multicenter, Retrospective, Real-world Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1354,
    "primaryOutcomeMeasure": "Disease-free survival up to 16 years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* (1)Female patients aged \u2265 18 years and \u2264 85 years\n* (2)The primary lesions and lymph nodes of the breast must meet all of the following conditions:\n\n  1. Histologically confirmed intraductal carcinoma of the breast, accompanied by microinvasion, with the infiltration range \u2264 1 mm;\n  2. Have received radical resection or breast conserving surgery;\n  3. Patients who have received breast conserving surgery must undergo pathological examination to confirm there is no residual cancer tissue on the cutting edge and receive postoperative radiotherapy within the prescribed dose and range;\n  4. No lymph node metastasis (including micrometastasis) is detected by postoperative pathological examination;\n  5. Immuno\n  6. Immunohistochemical staining results are positive for estrogen receptor (ER) or progesterone receptor (PR), which is defined as ER or PR immunoreactivity intensity \u22651+ or expression percentage \u2265 1%.\n* (3)A volunteer to participate in the study and willing to cooperate with follow-up\n\nExclusion Criteria:\n\n* (1)Patients with newly diagnosed metastatic breast cancer or other malignant tumors without breast intraductal carcinoma;\n* (2) Patients who have other malignant tumors before the initial diagnosis of intraductal carcinoma of the breast\n* (3) Patients who have received endocrine therapy with drugs including Toremifene, Tamoxifen, Anastrozole, Letrozole or Exemestane before the initial diagnosis of intraductal carcinoma of the breast\n* (4) Patients who have a serious comorbidity or other comorbidities that interfere with the conduct of the study, or those who are considered not suitable for participation in this study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}